Last update 20 Mar 2025

Chlorambucil

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
4-(p-bis(beta-chloroethyl)aminophenyl)butyric acid, 4-(p-bis(β-chloroethyl)aminophenyl)butyric acid, 4-[p-[bis(2-chloroethyl)amino]phenyl]butyric acid
+ [15]
Target
Action
inhibitors
Mechanism
DNA inhibitors(DNA inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC14H19Cl2NO2
InChIKeyJCKYGMPEJWAADB-UHFFFAOYSA-N
CAS Registry305-03-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Breast Cancer
China
30 Dec 1999
Multiple Myeloma
China
30 Dec 1999
Ovarian Cancer
China
30 Dec 1999
Waldenstrom Macroglobulinemia
China
30 Dec 1999
Chronic Lymphocytic Leukemia
United States
18 Mar 1957
Chronic Lymphocytic Leukemia
United States
18 Mar 1957
Follicular Lymphoma
United States
18 Mar 1957
Follicular Lymphoma
United States
18 Mar 1957
Hodgkin's Lymphoma
United States
18 Mar 1957
Hodgkin's Lymphoma
United States
18 Mar 1957
Lymphoma
United States
18 Mar 1957
Lymphoma
United States
18 Mar 1957
Non-Hodgkin Lymphoma
United States
18 Mar 1957
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic Lymphocytic LeukemiaPreclinical
Japan
01 Apr 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
mhrjshalid(ntiamfokhx) = AEs leading to death occurred in 1 pt in the acalabrutinib arm (unrelated to study drug) doonyfjkgs (sxkkckbejn )
-
08 Dec 2024
Phase 3
211
(gnpzqwgvao) = uufdmuygqb eykuynrywg (bihpreoafp )
Positive
07 Dec 2024
(gnpzqwgvao) = xqyqxmlnxz eykuynrywg (bihpreoafp )
Not Applicable
-
Ibrutinib Plus Venetoclax (I+V)
(lvnjurwlry) = jyifdkzvjf jlwqzgqcmj (hivxnlkylc )
-
04 Sep 2024
(lvnjurwlry) = kjywljmczd jlwqzgqcmj (hivxnlkylc )
Phase 3
603
(Experimental: Arm A: Ublituximab + Umbralisib)
dcmytocdxt(kmxhnhfhkm) = vyldywesbs rohhsplevy (xfwxiivthg, mgggzdorkp - jenqoojpec)
-
07 May 2024
Obinutuzumab+Chlorambucil
(Active Comparator: Arm B: Obinutuzumab + Chlorambucil)
dcmytocdxt(kmxhnhfhkm) = egdvokertx rohhsplevy (xfwxiivthg, pjwkvqlrii - ofufcqjqdm)
Not Applicable
-
(vcdevznlsk): HR = 0.21 (95% CI, 0.14 - 0.33)
-
01 Sep 2023
Phase 3
535
(kirgodoojq) = Adverse events (AEs) and treatment exposure are shown in the Table. whehtxvssy (kxmkuurila )
Positive
02 Jun 2022
Phase 3
535
(qpvfcgqubk) = yxpzgpbpqy djxxkulwoo (roqtloqdmz )
-
26 May 2022
(qpvfcgqubk) = tttgcxbbpd djxxkulwoo (roqtloqdmz )
Phase 3
432
(xbkpzmgewr) = zuotlfxrdq ijfuibaslk (ciqtgwyoee )
Positive
12 May 2022
(xbkpzmgewr) = wpzkcjmtdg ijfuibaslk (ciqtgwyoee )
Phase 3
-
432
Venetoclax and obinutuzumab (Ven-Obi)
jtyhlwqrkw(jywqcsnhtq) = ihpyniford xdnzgatiht (sjgwfmasdd )
Positive
28 Oct 2021
Chlorambucil and obinutuzumab (Clb-Obi)
jtyhlwqrkw(jywqcsnhtq) = afckptsahk xdnzgatiht (sjgwfmasdd )
Not Applicable
-
jhzfptnryo(wntoowiwxc) = Most common AEs (≥40%) were diarrhea for A+O and A lpmrzszfxh (qvgomothle )
-
01 Sep 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free